Transfer factor as an approach to the treatment of immune deficiency disease.
Use of transfer factor in the treatment of chronic mucocutaneous candidiasis is discussed. The clinical experience in treating 2 patients with different clinical expressions of the syndrome and their different responses to treatment with repeated injections of transfer factor given in conjunction with amphotericin-B are reported. Results indicate that this form of therapy is a safe and effective way of restoring cell-mediated immunity to Candida and successfully treating some patients with chronic mucocutaneous candidiasis.
D000666:Amphotericin B / Q000627:therapeutic use; D002176:Candida albicans / Q000276:immunology; D002179:Candidiasis, Cutaneous / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D002180:Candidiasis, Oral / Q000209:etiology; D002648:Child; D005260:Female; D006801:Humans; D007011:Hypoparathyroidism / Q000209:etiology; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000628:therapy*; D008213:Lymphocyte Activation; D010304:Paronychia / Q000209:etiology; D012882:Skin Tests; D013936:Thymidine / Q000378:metabolism; D014165:Transfer Factor / Q000627:therapeutic use*; D014316:Tritium; D014820:Vitiligo / Q000209:etiology
D014165:Transfer Factor; D014316:Tritium; D000666:Amphotericin B; D013936:Thymidine